Optimistic Outlook for Lucid Diagnostics: Buy Rating Amid Strong Q3 Performance and Future Growth Potential
In a report released today, Michael Matson from Needham maintained a Buy rating on Lucid Diagnostics (LUCD – Research Report), with a ...